ID   0467.3
AC   CVCL_A6HV
DR   Wikidata; Q107113125
RX   PubMed=3365703;
RX   PubMed=6286839;
CC   Group: Hybridoma fusion partner cell line.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C61255; Lesch-Nyhan syndrome
DI   ORDO; Orphanet_510; Lesch-Nyhan syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_J105 ! GM00467
SX   Female
AG   Age unspecified
CA   Transformed cell line
DT   Created: 20-05-21; Last updated: 29-06-23; Version: 4
//
RX   PubMed=3365703;
RA   Kjeldsen T.B., Rasmussen B.B., Rose C., Zeuthen J.;
RT   "Human-human hybridomas and human monoclonal antibodies obtained by
RT   fusion of lymph node lymphocytes from breast cancer patients.";
RL   Cancer Res. 48:3208-3214(1988).
//
RX   PubMed=6286839; DOI=10.1084/jem.156.3.930;
RA   Chiorazzi N., Wasserman R.L., Kunkel H.G.;
RT   "Use of Epstein-Barr virus-transformed B cell lines for the generation
RT   of immunoglobulin-producing human B cell hybridomas.";
RL   J. Exp. Med. 156:930-935(1982).
//